论文部分内容阅读
本实验通过结扎复制心肌缺血再灌流损伤模型，观察参麦注射液血浆丙二醛含量、溶酶体组织蛋白酶活性的影响。结果发现，心肌缺血30min和再灌流60min时，血浆丙二醛含量分别由缺血前1．53±0．36nmol／ml上升到3．86±0．47和4．82±0．53nmol／ml（P值均＜0．01），血浆组织蛋白酶D活性由缺血前的0．025±0．005U／mg蛋白质分别上升到缺血后30min时的0．049±0．003和再灌流60min时的0．087±0．008U／mg蛋白质（P值均＜0．01）。注射参麦注射液后再灌流60分钟，血浆丙二醛含量为3．83±0．36nmol／ml（与对照组相比P＜0．01）；组织蛋白酶D活性为0．055±0．007U／mg蛋白质（与对照组相比P＜0．01）。提示参表注射液在体内通过对抗心肌缺后再灌流中的氧自由基损伤和稳定溶酶体膜作用，保护心肌的缺血再灌流损伤。
In this experiment, myocardial ischemia and reperfusion injury models were duplicated by ligation to observe the effect of Shenmai injection on plasma malondialdehyde content and lysosomal cathepsin activity. The results showed that plasma MDA content increased from 1.53±0.36 nmol/ml before ischemia to 3.86±0.47 and 4.82±0.53 nmol/ml, respectively, at 30 min after myocardial ischemia and 60 min after reperfusion. In ml (P<0.01), the activity of plasma cathepsin D increased from 0.025±0.005 U/mg protein before ischemia to 0.049±0.003 at 30 min after ischemia and reperfusion. 0.087 ± 0.008 U/mg protein at 60 min (P <0.01). After injection of Shenmai injection for 60 minutes, the plasma malondialdehyde content was 3.83±0.36 nmol/ml (P<0.01 compared with the control group); cathepsin D activity was 0.055±0. 007 U/mg protein (P<0.01 compared to control). It is suggested that Shenqi injection protects myocardial ischemia and reperfusion injury by fighting oxygen free radicals in the reperfusion of myocardial insufficiency and stabilizing the lysosomal membrane.